ODI Pharma AB (ODI.ST)

SEK 2.68

(0.0%)

Total Liabilities Summary of ODI Pharma AB

  • ODI Pharma AB's latest annual total liabilities in 2023 was 10.05 Million SEK , up 79.19% from previous year.
  • ODI Pharma AB's latest quarterly total liabilities in 2023 FY was 10.05 Million SEK , up 79.19% from previous quarter.
  • ODI Pharma AB reported annual total liabilities of 5.61 Million SEK in 2022, up 354.26% from previous year.
  • ODI Pharma AB reported annual total liabilities of 1.23 Million SEK in 2021, up 112.41% from previous year.
  • ODI Pharma AB reported quarterly total liabilities of 5.3 Million SEK for 2023 Q2, down -7.68% from previous quarter.
  • ODI Pharma AB reported quarterly total liabilities of 10.05 Million SEK for 2023 Q4, down -15.98% from previous quarter.

Annual Total Liabilities Chart of ODI Pharma AB (2023 - 2018)

Historical Annual Total Liabilities of ODI Pharma AB (2023 - 2018)

Year Total Liabilities Total Liabilities Growth
2023 10.05 Million SEK 79.19%
2022 5.61 Million SEK 354.26%
2021 1.23 Million SEK 112.41%
2020 581.72 Thousand SEK -25.96%
2019 785.67 Thousand SEK 84.44%
2018 425.98 Thousand SEK 0.0%

Peer Total Liabilities Comparison of ODI Pharma AB

Name Total Liabilities Total Liabilities Difference
AcuCort AB 10.97 Million SEK 8.358%
AlzeCure Pharma AB (publ) 8.22 Million SEK -22.252%
BioGaia AB (publ) 302.84 Million SEK 96.679%
Enzymatica AB (publ) 49.3 Million SEK 79.6%
Enorama Pharma AB (publ) 14.84 Million SEK 32.258%
Gabather AB (publ) 6.87 Million SEK -46.23%
Klaria Pharma Holding AB (publ.) 31.98 Million SEK 68.556%
Moberg Pharma AB (publ) 24 Million SEK 58.105%
Nanexa AB (publ) 36.42 Million SEK 72.39%
Newbury Pharmaceuticals AB (publ) 38.95 Million SEK 74.181%
Orexo AB (publ) 727.7 Million SEK 98.618%
Probi AB (publ) 181.31 Million SEK 94.453%
Swedencare AB (publ) 2.31 Billion SEK 99.566%
Swedish Orphan Biovitrum AB (publ) 40.16 Billion SEK 99.975%
Toleranzia AB 6.9 Million SEK -45.574%
Vivesto AB 30.45 Million SEK 66.972%